Table 1.
Group | CD4 (P < 0.004) | CD8 (P > 0.32) | MHC-II (P < 0.012) | RTLA (P < 0.005) | CD18 (P < 0.11) |
---|---|---|---|---|---|
Untreated (ID) mean positive percentage ± SD | 4.41 ± 0.9 | 0.67 ± 0.2 | 8.5 ± 0.4 | 6.2 ± 0.9 | 8.7 ± 0.6 |
CsA-treated (ID/Rx) mean positive percentage ± SD | 0.75 ± 0.2 | 0.39 ± 0.1 | 6.6 ± 0.5 | 11.4 ± 1.7 | 7.5 ± 0.4 |
Compared to ID group, the CsA-treated group (ID/Rx) had a significant decrease of CD4+ (P < 0.008), MHC-II (P < 0.012), and RTLA (P < 0.005), and no significant change in CD18+ (P < 0.11).